Peer-reviewed veterinary case report
Furosemide lowers bladder bleeding risk in dogs on low-dose
By Setyo, L et al.·Published in Veterinary and comparative oncology·2017·Perth Veterinary Oncology, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
- Species:
- dog
Plain-English summary
A group of dogs receiving a cancer treatment called cyclophosphamide developed a condition known as sterile hemorrhagic cystitis (SHC), which causes bleeding in the bladder. Researchers found that giving furosemide, a diuretic, alongside cyclophosphamide significantly reduced the chances of dogs developing SHC. In fact, only 10% of dogs given furosemide experienced SHC, compared to over 30% of those who did not receive it. This suggests that furosemide can be an effective preventive measure for dogs undergoing this type of cancer treatment.
People also search for: dog cancer treatment side effects · furosemide for dog bladder problems · cyclophosphamide dog treatment risks
Abstract
Sterile haemorrhagic cystitis (SHC) is a known risk of cyclophosphamide treatment. Diuresis using furosemide is effective in canines when maximally tolerated dosed cyclophosphamide is administered. This retrospective study aimed to determine whether orally administered furosemide decreased the incidence of SHC. Secondary aims were to identify predisposing factors for SHC. One-hundred and fifteen dogs treated with metronomic cyclophosphamide were analysed retrospectively. Populations were not randomized. 25 dogs (21.7%) developed SHC. Furosemide administration significantly reduced the likelihood of SHC development (P = 0.010, where SHC was diagnosed in 30.3% of dogs administered cyclophosphamide without furosemide, and 10.2% of dogs administered cyclophosphamide with furosemide). Age, gender, breed, bodyweight, number of cyclophosphamide treatments, piroxicam use and previous or pre-existing disease were not found to be associated with SHC development. This study demonstrates furosemide is effective in the prevention of SHC and its use may be considered when implementing metronomic cyclophosphamide therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28194917/